Related references
Note: Only part of the references are listed.In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives
Julia K. J. Ahlskog et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
Christoph Schliemann et al.
BLOOD (2009)
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
Stefanie Sauer et al.
BLOOD (2009)
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours
J. K. J. Ahlskog et al.
BRITISH JOURNAL OF CANCER (2009)
Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis
Maria Vincenza Carriero et al.
MOLECULAR CANCER THERAPEUTICS (2009)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer
Marta Pedretti et al.
LUNG CANCER (2009)
A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells
Kathrin Zuberbuehler et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2009)
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis
Kathrin Schwager et al.
ARTHRITIS RESEARCH & THERAPY (2009)
DNA-encoded chemical libraries for the discovery of MMP-3 inhibitors
Joerg Scheuermann et al.
BIOCONJUGATE CHEMISTRY (2008)
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo
Alessandra Villa et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies
Lisa Berglund et al.
MOLECULAR & CELLULAR PROTEOMICS (2008)
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent
Mark S. Dennis et al.
CANCER RESEARCH (2007)
Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo
Michela Silacci et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer
Hilary Hardy Street et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2006)
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C
Simon S. Brack et al.
CLINICAL CANCER RESEARCH (2006)
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers
GP Adams et al.
CLINICAL CANCER RESEARCH (2006)
Antibody targeted drugs as cancer therapeutics
D Schrama et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Design, construction, and characterization of a large synthetic human antibody phage display library
M Silacci et al.
PROTEOMICS (2005)
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice
K Almholt et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents
A Schweinitz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer
MJ Duffy et al.
CLINICAL BIOCHEMISTRY (2004)
Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain
KS Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2003)
Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins
U Reuning et al.
BIOLOGICAL CHEMISTRY (2003)
Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma
A Chrastina et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Stromal antigen targeting by a humanised monoclonal antibody:: An early phase II trial of sibrotuzamab in patients with metastatic colorectal cancer
RD Hofheinz et al.
ONKOLOGIE (2003)
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin
P Castellani et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin
L Borsi et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor:: a potential target for anti-invasive cancer therapy
M Ploug et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2002)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients
MP Look et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors
SY Tamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
The plasminogen activation system in tumor growth, invasion, and metastasis
PA Andreasen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2000)
Share Paper
